Comparison Chart Outlook Therapeutics, Inc.
Stocks
OTLK
US69012T3059
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.7000 USD | +4.14% |
|
-39.13% | -55.70% |
| 08-17 | EyePoint's drug for age-related eye disease fails late-stage trial, shares tank | RE |
| 08-17 | Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Other Biotechnology & Medical Research | +4.14% | -39.13% | -55.70% | -70.09% | -98.47% | 126M |  |  | |
- Stock Market
- Stocks
- OTLK Stock
- Charts Outlook Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
